Skip to content

Multiple and central nervous system extranodal involvement predict poor prognosis in R/R DLBCL following CD19 CAR-T therapy.

Nov 2026 · Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis · Vol 171, pp. 108367 · 0 citations · 21 references
Medicine

Abstract

Background

CD19 chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable results in treating patients with refractory or relapsed diffuse large B-cell lymphoma (R/R DLBCL). Nevertheless, certain limitations still persist. This study focuses on the impact of extranodal involvement before treatment on the efficacy and prognosis of CD19 CAR-T cell therapy in patients with DLBCL, aiming to accurately identify the patient subgroups with poor treatment response and unfavorable long-term survival outcomes. We hope to optimize the treatment methods so that these patients can benefit from it.

Method

We retrospectively collected the clinical information of 70 patients with R/R DLBCL who received CD19 CAR-T cell therapy in a single center. Through subgroup analysis, we evaluated whether extranodal involvement affects the long-term survival of patients treated with CD19 CAR-T cells. We analyzed the treatment outcomes of patients with extranodal involvement based on the site and number. And through the Cox proportional-hazards regression model, we explored the independent risk factors affecting the survival of patients treated with CD19 CAR-T cells. RESULT The number and sites of extranodal involvement in patients with DLBCL affect treatment outcomes and long-term survival. Patients with more than two involved sites had significantly shorter overall survival compared to those with involvement in two or fewer sites (Mann-Whitney U test: χ² = 11.40, P = 0.0007). As the number of extranodal involved sites increases, the therapeutic effect of CD19 CAR-T cells in treating DLBCL deteriorates. In patients with involvement in more than two sites, the complete response rate after CD19 CAR-T cell therapy was only 15.38%. Based on the analysis, we identified the number of extranodal sites involved (HR = 0.203, 95% CI: 0.051-0.810, P = 0.024) and central nervous system involvement (HR = 3.552, 95% CI: 1.074-11.748, P = 0.038) as independent factors affecting prognosis in DLBCL patients receiving CD19 CAR-T cell therapy.

Conclusion

When considering CD19 CAR-T cell therapy for patients with DLBCL, special attention should be paid to whether there is extranodal involvement, especially multiple-site involvement and central nervous system involvement.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.